Guideline Recommendations for Alternatives to Mesalamine in Mild‑to‑Moderate Ulcerative Colitis

First‑Line Non‑Mesalamine Alternatives

The American Gastroenterological Association (AGA) recommends sulfasalazine (2–4 g/day) or diazo‑bonded 5‑ASA agents (balsalazide, olsalazine) as the primary alternatives for patients with mild‑to‑moderate ulcerative colitis who cannot use mesalamine, acknowledging higher intolerance rates compared with mesalamine. 1
Balsalazide and olsalazine deliver 5‑ASA to the colon through azo‑bond cleavage, providing a targeted release mechanism. 1, 2
The AGA places diazo‑bonded 5‑ASA agents at the same recommendation level as standard‑dose mesalamine for extensive mild‑moderate disease. 1
Olsalazine is associated with secretory diarrhea as a notable adverse effect. 3
Recommended dosing ranges:
- Balsalazide 2–6.75 g/day (equivalent to 0.7–2.4 g/day 5‑ASA)
- Olsalazine 2–3 g/day (equivalent to 1.6–2.4 g/day 5‑ASA)

Sulfasalazine 2–4 g/day is especially appropriate for patients already in remission on this drug or those with prominent arthritic symptoms, particularly when cost constraints exist. 1, 5
The AGA notes that sulfasalazine has a higher intolerance rate than mesalamine. 1
Sulfasalazine consists of 5‑ASA linked to sulfapyridine; the sulfapyridine moiety is responsible for most adverse effects. 3

For patients refractory to optimized oral and rectal 5‑ASA therapy, the AGA suggests adding either oral prednisone or budesonide MMX, irrespective of disease extent. 5, 3, 6
In cases of proctosigmoiditis or proctitis where mesalamine suppositories are intolerable or ineffective, rectal corticosteroid therapy is recommended over no therapy. 5, 3
Rectal corticosteroid foam preparations may be chosen by patients who prioritize ease of use (avoiding mesalamine enemas) over maximal efficacy. 1, 3

All 5‑ASA alternatives require periodic renal function monitoring, as advised by the AGA. 3
Rare but serious adverse events include interstitial nephritis and idiosyncratic worsening of colitis. 3

The AGA makes no recommendation for probiotics, curcumin, or fecal microbiota transplantation outside of clinical trials for mild‑moderate ulcerative colitis. 1, 5, 6
Use of these unproven modalities may delay effective treatment and increase the risk of symptom worsening or complications. 2

For isolated proctitis, mesalamine suppositories remain strongly recommended even when oral mesalamine is not tolerated. 5, 7
For extensive or left‑sided disease, the AGA advises combining oral and rectal therapies before switching to a different class of agents. 1, 2